Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suiyuan Hu

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Mediators of Inflammation|September 10, 2021
The Biological Disease-Modifying Antirheumatic Drugs and the Risk of Cardiovascular Events: A Systematic Review and Meta-AnalysisSuiyuan Hu, Chu Lin, Xiaoling Cai, et al.
Eclinicalmedicine|March 3, 2023
Trends in baseline HbA1c and body-mass index in randomised placebo-controlled trials of type 2 diabetes from 1987 to 2022: a systematic review and meta-analysisSuiyuan Hu, Chu Lin, Xiaoling Cai, et al.
Pharmacological Research|March 26, 2024
The opportunities and challenges of the disease-modifying immunotherapy for type 1 diabetes: A systematic review and meta-analysisChu Lin, Suiyuan Hu, Xiaoling Cai, et al.
Acta Diabetologica|January 7, 2023
Baseline eGFR, albuminuria and renal outcomes in patients with SGLT2 inhibitor treatment: an updated meta-analysisYunke Ma, Chu Lin, Xiaoling Cai, et al.
Expert Review of Clinical Pharmacology|July 15, 2022
The association between the use of sodium glucose cotransporter 2 inhibitor and the risk of diabetic retinopathy and other eye disorders: a systematic review and meta-analysisYunke Ma, Chu Lin, Xiaoling Cai, et al.
Atherosclerosis|August 1, 2023
Anti-inflammatory therapies were associated with reduced risk of myocardial infarction in patients with established cardiovascular disease or high cardiovascular risks: A systematic review and meta-analysis of randomized controlled trialsZonglin Li, Chu Lin, Xiaoling Cai, et al.
European Journal of Internal Medicine|January 11, 2023
Is the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes?Shuzhen Bai, Chu Lin, Ruoyang Jiao, et al.
Expert Opinion on Investigational Drugs|August 15, 2022
Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participantsZonglin Li, Chu Lin, Jinyu Zhou, et al.
Diabetes, Obesity & Metabolism|February 22, 2023
Population attributable fractions of modifiable risk factors for microvascular complications of type 2 diabetes in China: An analysis using national cross-sectional dataChu Lin, Xingyun Zhu, Ruoyang Jiao, et al.
Annals of Medicine|December 13, 2025
Intensive blood pressure reduction but an increased risk of peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trialsRuoyang Jiao, Chu Lin, Zonglin Li, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Mediators of Inflammation|September 10, 2021
The Biological Disease-Modifying Antirheumatic Drugs and the Risk of Cardiovascular Events: A Systematic Review and Meta-AnalysisSuiyuan Hu, Chu Lin, Xiaoling Cai, et al.
Eclinicalmedicine|March 3, 2023
Trends in baseline HbA1c and body-mass index in randomised placebo-controlled trials of type 2 diabetes from 1987 to 2022: a systematic review and meta-analysisSuiyuan Hu, Chu Lin, Xiaoling Cai, et al.
Pharmacological Research|March 26, 2024
The opportunities and challenges of the disease-modifying immunotherapy for type 1 diabetes: A systematic review and meta-analysisChu Lin, Suiyuan Hu, Xiaoling Cai, et al.
Acta Diabetologica|January 7, 2023
Baseline eGFR, albuminuria and renal outcomes in patients with SGLT2 inhibitor treatment: an updated meta-analysisYunke Ma, Chu Lin, Xiaoling Cai, et al.
Expert Review of Clinical Pharmacology|July 15, 2022
The association between the use of sodium glucose cotransporter 2 inhibitor and the risk of diabetic retinopathy and other eye disorders: a systematic review and meta-analysisYunke Ma, Chu Lin, Xiaoling Cai, et al.
Atherosclerosis|August 1, 2023
Anti-inflammatory therapies were associated with reduced risk of myocardial infarction in patients with established cardiovascular disease or high cardiovascular risks: A systematic review and meta-analysis of randomized controlled trialsZonglin Li, Chu Lin, Xiaoling Cai, et al.
European Journal of Internal Medicine|January 11, 2023
Is the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes?Shuzhen Bai, Chu Lin, Ruoyang Jiao, et al.
Expert Opinion on Investigational Drugs|August 15, 2022
Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participantsZonglin Li, Chu Lin, Jinyu Zhou, et al.
Diabetes, Obesity & Metabolism|February 22, 2023
Population attributable fractions of modifiable risk factors for microvascular complications of type 2 diabetes in China: An analysis using national cross-sectional dataChu Lin, Xingyun Zhu, Ruoyang Jiao, et al.
Annals of Medicine|December 13, 2025
Intensive blood pressure reduction but an increased risk of peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trialsRuoyang Jiao, Chu Lin, Zonglin Li, et al.
Pageof 3